Revenue: As of FY2027 Q1, the actual value is USD 1.476 M, beating the estimate of USD 166.67 K.

EPS: As of FY2027 Q1, the actual value is USD -0.3, beating the estimate of USD -0.365.

EBIT: As of FY2027 Q1, the actual value is USD -13.03 M.

The provided reference, a FORM 8-K filing by Vistagen Therapeutics, Inc., announces the issuance of a press release detailing financial results for its fiscal year 2027 first quarter ended June 30, 2026. However, the actual financial results, operational metrics, cash flow information, or outlook/guidance are not included within this FORM 8-K document itself. The reference explicitly states that no specific financial or operational metrics, nor any outlook or guidance, can be extracted from the given text, as this information is contained in the referenced Exhibit 99.1 (the press release), which is not part of the provided content.